Co-Author
This page shows the publications co-authored by Donna Neuberg and Jeffrey Zwicker.
Connection Strength
2.935
-
Antiplatelet medications and risk of intracranial hemorrhage in patients with metastatic brain tumors. Blood Adv. 2022 Mar 08; 6(5):1559-1565.
Score: 0.248
-
Overall survival with warfarin vs. low-molecular-weight heparin in cancer-associated thrombosis. J Thromb Haemost. 2021 11; 19(11):2825-2834.
Score: 0.240
-
Heparin induced thrombocytopenia antibodies in Covid-19. Am J Hematol. 2020 Jul 13.
Score: 0.221
-
Anticoagulation after intracranial hemorrhage in brain tumors: Risk of recurrent hemorrhage and venous thromboembolism. Res Pract Thromb Haemost. 2020 Jul; 4(5):860-865.
Score: 0.220
-
Dose-adjusted enoxaparin thromboprophylaxis in hospitalized cancer patients: a randomized, double-blinded multicenter phase 2 trial. Blood Adv. 2020 05 26; 4(10):2254-2260.
Score: 0.219
-
Targeting protein disulfide isomerase with the flavonoid isoquercetin to improve hypercoagulability in advanced cancer. JCI Insight. 2019 02 21; 4(4).
Score: 0.201
-
Intracranial hemorrhage with direct oral anticoagulants in patients with brain tumors. J Thromb Haemost. 2019 01; 17(1):72-76.
Score: 0.198
-
Predicting the higher rate of intracranial hemorrhage in glioma patients receiving therapeutic enoxaparin. Blood. 2017 06 22; 129(25):3379-3385.
Score: 0.177
-
Protein disulfide isomerase inhibition blocks thrombin generation in humans by interfering with platelet factor V activation. JCI Insight. 2017 01 12; 2(1):e89373.
Score: 0.173
-
Intracranial hemorrhage in patients with brain metastases treated with therapeutic enoxaparin: a matched cohort study. Blood. 2015 Jul 23; 126(4):494-9.
Score: 0.155
-
Pattern of frequent but nontargeted pharmacologic thromboprophylaxis for hospitalized patients with cancer at academic medical centers: a prospective, cross-sectional, multicenter study. J Clin Oncol. 2014 Jun 10; 32(17):1792-6.
Score: 0.144
-
Prediction and prevention of thromboembolic events with enoxaparin in cancer patients with elevated tissue factor-bearing microparticles: a randomized-controlled phase II trial (the Microtec study). Br J Haematol. 2013 Feb; 160(4):530-7.
Score: 0.131
-
Biased estimation of thrombosis rates in cancer studies using the method of Kaplan and Meier. J Thromb Haemost. 2012 Jul; 10(7):1449-51.
Score: 0.127
-
Accounting for death as a competing risk in cancer-associated thrombosis studies. Thromb Res. 2012 Apr; 129 Suppl 1:S85-7.
Score: 0.124
-
Tumor-derived tissue factor-bearing microparticles are associated with venous thromboembolic events in malignancy. Clin Cancer Res. 2009 Nov 15; 15(22):6830-40.
Score: 0.105
-
Timing of postpartum enoxaparin administration and severe postpartum hemorrhage. Blood Coagul Fibrinolysis. 2008 Jan; 19(1):55-9.
Score: 0.093
-
Anticoagulation in cancer-associated thromboembolism with thrombocytopenia: a prospective, multicenter cohort study. Blood Adv. 2021 12 28; 5(24):5546-5553.
Score: 0.061
-
Pregnancy outcomes, risk factors, and cell count trends in pregnant women with essential thrombocythemia. Leuk Res. 2020 11; 98:106459.
Score: 0.056
-
Individualized vaccination of AML patients in remission is associated with induction of antileukemia immunity and prolonged remissions. Sci Transl Med. 2016 12 07; 8(368):368ra171.
Score: 0.043
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.